BioSpace News Archive

Opthea Limited announces the presentation of novel clinical data at the upcoming Association for Research in Vision and Ophthalmology 2022 conference, taking place in Denver, CO from May 1-4, 2022 and virtually from May 11-12, 2022.

Gelesis, a consumer-focused biotherapeutics company and the maker of Plenity®, released a poster presentation at the World of Microbiome annual meeting in Vienna.

Nutriband Inc., a developer of transdermal pharmaceutical products, announced financial and operational results for the fiscal year ended January 31, 2022.

Zymergen Inc. (“Zymergen” or the “Company”), today announced the company will be participating in the upcoming BofA Securities 2022 Healthcare Conference held in Las Vegas, NV.

Shenzhen IONOVA Life Science Co., Ltd. announces today it has entered into a clinical trial collaboration agreement with MSD (Merck & Co., Inc., Kenilworth, NJ., USA) to evaluate clinical benefits of INV-1120, IONOVA’s EP4 antagonist, in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for cancer treatment.

Immutep Limited provides an update on the ongoing development of its product candidates, eftilagimod alpha and IMP761 for the quarter ended 31 March 2022.

Heska Corporation plans to host its 2022 Investor Day in a virtual format on Tuesday, May 17, 2022 at 9:00 a.m. MT / 11:00 a.m. ET.

Biocytogen Pharmaceuticals ( Beijing ) Co., Ltd. (Biocytogen) announced that it has entered into an evaluation and option agreement with Merck KGaA, Darmstadt, Germany to grant them a sole license to evaluate Biocytogen’s proprietary antibodies against at least three distinct targets with an option to acquire some of the assets at a later date for therapeutic product development for all uses worldwide.

Syneos Health, the only fully integrated biopharmaceutical solutions organization, reported financial results for the three months ended March 31, 2022.

Merck, known as MSD outside the United States and Canada, announced that the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of microsatellite instability-high or deficient mismatch repair tumors in adults.